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Abstract: BACKGROUND We report the analysis involving patients treated on the initial CODEL
design. METHODS Adults (>18) with newly-diagnosed 1p/19q WHO grade III oligodendroglioma were
randomized to RT (5940 cGy) alone (Arm A); RT with concomitant and adjuvant temozolomide (TMZ)
(Arm B); or TMZ alone (Arm C). Primary endpoint was overall survival (OS), Arm A versus B. Secondary
comparisons were performed for OS and progression-free survival (PFS), comparing pooled RT arms
versus TMZ-alone arm. RESULTS Thirty-six patients were randomized equally. At median follow-up of
7.5 years, 83.3% (10/12) TMZ-alone patients progressed, versus 37.5% (9/24) on the RT arms. PFS was
significantly shorter in TMZ-alone patients compared to RT-treated patients (HR=3.12; 95% CI: 1.26,
7.69; p=0.014). Death from disease progression occurred in 3/12 (25%) of TMZ-alone patients and 4/24
(16.7%) on the RT Arms. OS did not statistically differ between arms (comparison underpowered). After
adjustment for IDH status (mutated/wildtype) in a Cox regression model utilizing IDH and RT treatment
status as co-variables (Arm C vs pooled Arms A+B), PFS remained shorter for patients not receiving
RT, (HR= 3.33; 95% CI: 1.31, 8.45; p=0.011), but not OS ((HR = 2.78; 95% CI 0.58, 13.22, p=0.20).
Grade 3+ adverse events occurred in 25%, 42% and 33% of patients (Arms A, B, and C). There were no
differences between Arms in neurocognitive decline comparing baseline to 3 months. CONCLUSIONS
TMZ-alone patients experienced significantly shorter PFS than patients treated on the RT Arms. The
ongoing CODEL trial has been redesigned to compare RT+PCV versus RT+TMZ.
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Importance of the study:  
The initial CODEL Phase III randomized trial for patients with newly diagnosed 1p/19q 
codeleted anaplastic oligodendroglial tumors gliomas compared survival outcome following 
radiotherapy (RT) alone (control arm) vs. RT with concurrent and adjuvant temozolomide 
(TMZ). A third TMZ-alone exploratory randomization arm was included as well, based on 
common clinical practice at the time of design. The RT-alone control arm was changed to RT + 
adjuvant PCV following reports from EORTC 26951 and RTOG 9402, which showed a survival 
benefit of added PCV for this cohort. In our analysis of the patients treated on the original 
CODEL design, we found that TMZ-alone treated patients experienced significantly shorter PFS 
than patients treated on the RT Arms. When combined with prior reported data, our results 

















BACKGROUND:  We report the analysis involving patients treated on the initial 
CODEL design. METHODS: Adults (>18) with newly-diagnosed 1p/19q WHO grade III 
oligodendroglioma were randomized to RT (5940 cGy) alone (Arm A); RT with concomitant 
and adjuvant temozolomide (TMZ) (Arm B); or TMZ alone (Arm C). Primary endpoint was 
overall survival (OS), Arm A versus B. Secondary comparisons were performed for OS and 
progression-free survival (PFS), comparing pooled RT arms versus TMZ-alone arm. RESULTS: 
Thirty-six patients were randomized equally. At median follow-up of 7.5 years, 83.3% (10/12) 
TMZ-alone patients progressed, versus 37.5% (9/24) on the RT arms. PFS was significantly 
shorter in TMZ-alone patients compared to RT-treated patients (HR=3.12; 95% CI: 1.26, 7.69; 
p=0.014). Death from disease progression occurred in 3/12 (25%) of TMZ-alone patients 
and 4/24 (16.7%) on the RT Arms. OS did not statistically differ between 
arms (comparison underpowered). After adjustment for IDH status (mutated/wildtype) in a Cox 
regression model utilizing IDH and RT treatment status as co-variables (Arm C vs pooled Arms 
A+B), PFS remained shorter for patients not receiving RT, (HR= 3.33; 95% CI: 1.31, 8.45; 
p=0.011), but not OS ((HR = 2.78; 95% CI 0.58, 13.22, p=0.20). Grade 3+ adverse events 
occurred in 25%, 42% and 33% of patients (Arms A, B, and C). There were no differences 
between Arms in neurocognitive decline comparing baseline to 3 months. CONCLUSIONS: 
TMZ-alone patients experienced significantly shorter PFS than patients treated on the RT Arms. 








 CODEL (NCCTG/Alliance for Clinical Trials in Oncology N0577; European 
Organisation for Research and Treatment Center (EORTC) 26081-22086; NRG 1071;  
Canadian Cancer Trials Group (CCTG) CEC.6) is an ongoing National Cancer Institute (NCI)-
sponsored, international intergroup, prospective randomized phase III trial for patients with 
newly diagnosed 1p/19q codeleted oligodendroglial tumors. The original design included 
randomization of patients to radiotherapy (RT) alone (Arm A); RT plus concomitant and 
adjuvant temozolomide (TMZ) (Arm B); or TMZ alone (Arm C). The primary objective of the 
trial was to compare overall survival (OS) between patients on Arms A and B. A secondary 
analysis compared OS and progression-free survival (PFS) between patients treated with RT (on 
the pooled Arms A + B) versus Arm C patients. After active enrollment began, results from 
RTOG 9402 and EORTC 26951 became available, which showed a survival benefit with the 
addition of  procarbazine, lomustine and vincristine (PCV) to RT versus RT alone.1, 2 
Accordingly, CODEL was redesigned, replacing the RT alone control arm with RT followed by 
adjuvant PCV, using the schedule utilized in EORTC 26951. Later, the TMZ-alone treatment 
arm was dropped, in part due to the findings from the current analysis. As the data from the 
initial patients enrolled in CODEL will not be utilized in the primary analysis for the redesigned 
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Eligible patients included adults (age > 18 years) with newly diagnosed, 1p/19q codeleted 
WHO grade III anaplastic oligodendroglial tumors. In the North American patients, histologic 
diagnosis and 1p/19q status were centrally confirmed at the Alliance/NCCTG central laboratory 
at Mayo Clinic (C.G., R.J.); in EORTC, pathology was centrally confirmed and 1p/19q 
codeletion status determined in the process of screening for EORTC 26053-22054 (CATNON). 
Isocitrate dehydrogenase (IDH) status was not required for eligibility, but was retrospectively 
obtained in 35/36 (97%) of patients, as determined by immunohistochemistry (IHC) for IDH 
R132H, or by sequencing. If IDH status was not known, tumor tissue banked per protocol was 
evaluated by IHC for IDH in the Pathology Research Core, Mayo Clinic Rochester., For those 
found to be IDH wild- type (WT) by IHC and with tumor tissue available, ,sequencing for IDH 1 
and 2 was performed at the  Clinical Genomics Laboratory, Mayo Clinic, Rochester MN.  
 
Additional eligibility criteria included that patients:  were  < 3 months from surgical 
diagnosis and recovered from effects of surgery; had acceptable hematologic parameters 
(absolute neutrophil count (ANC) > 1500 / uL; platelet count > 100,000 / uL; hemoglobin > 9 
gm/dL, serum total bilirubin < 3 times upper limit of normal (ULN), aspartate aminotransferase 
(AST) < 3 times ULN, and creatinine <  1.5 ULN); had Eastern Cooperative Oncology Group 
(ECOG) performance status 0-2; were willing to provide tissue samples for translational research 
studies; were able to complete neurocognitive testing and quality of life questionnaire without 
assistance; and were able to provide informed, written consent. Women of child-bearing 
potential had a negative pregnancy test, and expressed willingness to use contraception. Patients 
were ineligible if they had comorbid medical conditions compromising safety on this treatment; 
were immunocompromised (other than receiving steroids); had active serious infection or history 
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of HIV infection; had recent (< 6 months) history of myocardial infarction or congestive heart 
failure; had another active malignancy, with the exception of non-melanomatous skin or cervical 
cancer; or were receiving other active therapies directed at the central nervous system neoplasm.  
Study participants were required to sign Institutional Review Board-approved, protocol-
specific informed consent documents in accordance with federal, and institutional guidelines. 
Site participation required protocol approval by local institutional review boards, in accordance 
with assurances filed with the U.S. Department of Health and Human Services, or as required 
by the applicable national legislation of non-US countries. The study was performed in 
accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its 
later amendments or comparable ethical standards. The trial is registered in the public domain 
(clinicaltrials.gov; NCT00887146). 
 
Study Design and Treatment 
 
 Patients were randomized to Arm A, RT (5940 cGy in 33 fractions) alone; Arm B, RT + 
concomitant TMZ (75mg / m2 /day) followed by adjuvant TMZ (150-200 mg / m2, days 1-5 
every 28 days) for up to 12 cycles; or Arm C, TMZ alone (150-200 mg / m2, days 1-5 every 28 
days for up to 12 cycles (Figure 1). The decision to extend TMZ treatment beyond 6 cycles, for 
up to 12 cycles, was left to the treating investigator, without protocol-defined progression or 
development of adverse events meeting criteria for discontinuation of therapy.  Patients were 
randomized in a 1:1:1 fashion with the following stratification factors: age (> 50 versus ≤ 50 
years), registering group (NCI/CCTG versus EORTC), and ECOG performance status (0-1 
versus 2). Temozolomide was provided initially by Schering-Plough, and later Merck 
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Pharmaceuticals, Kenilworth, NJ.  Prophylaxis for Pneumocystis jirovecii was required in 
patients receiving temozolomide.  
 
For North American sites, the radiation treatment volume was defined as the T2 
hyperintensity on FLAIR (fluid-attenuated inversion recovery) or T2-weighted MR images 
including the surgical cavity, with a 1.0 cm margin anatomically constrained, plus a 5 mm 
planning target volume (PTV) margin to account for daily setup variation.  This volume received 
5040 cGy in 28 daily fractions if a sequential boost technique was used or 5445 cGy in 33 daily 
fractions if a concomitant boost technique was utilized.  If enhancing tumor was present, this 
represented the boost volume with the resection cavity, plus a 5-mm PTV margin.  If no tumor 
enhancement, the boost was defined as the original volume, but with no extra margin, except for 
the 5-mm PTV margin.  For sequential boost technique, 900 cGy was administered in 5 daily 
fractions (total dose 5940 cGy in 33 daily fractions).  For concomitant boost technique, the total 
dose to the boost volume was 5940 cGy in 33 daily fractions. EORTC sites utilized a single 
Gross Tumor Volume target (with no boost), defined as the entire region of T2 hyperintensity 
plus the region of enhancement on either the post- operative MRI (if available), or on the 




In the initial CODEL study, the primary endpoint was the comparison of OS between 
Arm A versus Arm B. OS was measured from the time of randomization until death. Secondary 
endpoints included comparison of PFS (Arm A vs B) and time to neurocognitive progression 
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(Arm C vs Arm B). However, this initial study was temporarily closed prematurely at the request 
of the Alliance Data Safety Monitoring Committee, in part due to the data observations regarding 
Arm C patients, and due to reports from the late analyses of RTOG 9402 and EORTC 26951 
which impacted the control arm of this initial CODEL study. Adequate events were not observed 
for the protocol-defined primary and secondary endpoint comparisons. Thus, we performed an 
initially unplanned secondary analysis to compare PFS of patients randomized to Arm C to the 
pooled Arm A and B patients. PFS was measured as the time from randomization until 
investigator-defined progression (earliest of either clinical progression or radiographic 
progression, protocol-defined per NCCTG criteria3 (see Supplemental Material), or death 
without documented progression. Patients alive at the time of analysis (5/4/2020) were censored 
at their last follow- up date. Patients having biopsy or subtotal resection were evaluated for 
clinical and radiographic response utilizing NCCTG criteria and designated as either complete 
response, partial response (PR), or regression (REGR) sustained at least 4 weeks; or as 
progression (PROG), as compared with the pre-treatment baseline assessment. 
 
Neurocognitive timepoints varied slightly by arm, and compliance with the schedule was 
limited. Thus, the only meaningful analysis that could be conducted compared baseline 
assessments with those competed within the first 3 months of treatment. A Reliable Change 
Index (RCI), representing the 90% confidence interval for test-retest variability (RCI90) was 
utilized to compare baseline and 3 month subtests. Cognitive decline was defined as a worsening 
from baseline greater than the respective RCI90 normative values on any one of the following 
subtests: Hopkins Verbal Learning Test-Revised (HVLT-R) 4; Total Recall, Delayed Recall, and 
Delayed Recognition; Controlled Oral Word Association (COWA) 5; or Trail Making Test Part A 
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and B6. Credentialing of site personnel was required for administration of cognitive testing (J.C., 
J.W or M.K). Quality of life (QoL) was assessed via two instruments: the EORTC quality of life 
questionnaire core-30 (QLQ-C30, version 3) and EORTC quality of life questionnaire-brain 
cancer module (QLQ-BN20). The protocol defined schedule for cognitive testing and QoL 
reporting was baseline, 4-6 weeks post RT (Arms A and B), or at the beginning of every other 
treatment cycle (Arm C), then 8 weeks for 18 months, then every 12 weeks until progression.  
 
 Adverse events were evaluated with the NCI Common Terminology Criteria for Adverse 
Events (CTCAE) version 3.0. Arms A and B assessments (neurological exam, neuroimaging, and 
blood profiles) were performed at baseline, 4-6 weeks post RT, and at the beginning of every 
other treatment cycle (Arm C), then every 8 weeks for 18 months, and then every 12 weeks until 
progression. Patients who progressed were followed clinically until death.  Per protocol, MRI 
scans were required unless contraindicated (e.g., presence of pacemaker), in which case CT 
scans were allowed; however in review, all patients were followed by MRI. Sites were required 




 The study was powered to detect OS hazard ratio (HR) of 0.67 or less when comparing 
Arm B to Arm A. A sample size of 219 patients per arm would have 80% power with a one-
sided alpha = 0.05 using a log rank test, 7 assuming the median survival for the control arm (Arm 
A) was 7.2 years. The final OS analysis was to be performed when 178 deaths were observed. 
The sample size for the secondary analysis, comparing PFS between Arm C and Arms A and B, 
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was to include 50 patients in Arm C and 100 patients in Arms A and B ,  performed when 75 
progression events were observed. All analyses were based on the intention-to-treat principle, 
with all eligible patients belonging to the treatment arm to which they were randomized. The 
distributions of OS and PFS were estimated using the Kaplan-Meier method 8 along with median 
survival, and corresponding 95% confidence intervals (CI). The differences between Kaplan-
Meier survival curves were evaluated with a log rank test. Cox models were used to generate 
point estimates and hazard ratios (HRs) for comparisons between arms, comparisons between 
IDH mutation status, and for comparisons between arms while adjusting for IDH mutation status.  
Differences in the proportions of patients with grade 3+ adverse events among/between treatment 
arms were evaluated with a chi-square test.  Neurocognitive analysis across the three arms was 
based on the change from baseline to the 3-months evaluation. Differences in proportions of 
patients with cognitive decline among/between treatment were evaluated with a chi-square test.  
QoL analysis across all three arms was based on the change from baseline to the 3-month QLQ-
C30 and QLQ-BN20 evaluations. Change-from-baseline values were compared across the arms 
using the Kruskal-Wallis test. All analyses were completed with SAS version 9.4M5. 
Data collection and statistical analyses were conducted by the Alliance Statistics and Data 
Center. Data quality was ensured by review of data by the Alliance Statistics and Data Center 
and by the study chairperson following Alliance policies. The study was monitored by the 
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 Thirty-six patients with 1p/19q codeleted anaplastic (WHO Grade III) glioma were 
randomized between November, 2009 and December, 2011 (Arm A-12; Arm B-12; Arm C-12) 
and included in this analysis. The North American NCI-Sponsored Cooperative Groups accrued 
19 patients (53%) and EORTC accrued 17 patients (47%).The treatment arms were balanced for 




 There were 8 deaths: 3 on Arm A, 1 on Arm B, and 4 on Arm C. The median follow-up 
was 7.5 years. Overall survival time (FIGURE 2) was not statistically different between RT 
alone (Arm A) and RT+TMZ (Arm B) with median OS was not reached in either arm (Figure 
2A); (HR 2.74 (95% CI: 0.28 to 26.43 log rank p-value = 0.36); however, this comparison is 
significantly underpowered. OS difference also failed to reach statistical significance with regard 
to patients treated on Arm C, compared to the patients on Arms A and B combined (log rank p-
value = 0.27, Figure 2B). The median OS was not reached in either group, with observed HR 
2.14 (95% CI: 0.53 to 8.61). The 3- and 5-year OS rates were 75% and 67%, respectively, for 
TMZ-alone Arm C patients compared to 96% and 91% for patients treated with RT (Arms A 
andB ). When comparing patients treated without TMZ (Arm A) versus those treated with TMZ 
(pooled Arms B+C), there were no significant differences in PFS (median = 4.2 yrs. vs. 6.5 yrs., 
respectively; HR=1.44, 95% CI: 0.58 to 3.60; log rank p=0.43) or OS (neither reached median; 
HR=1.12, 95% CI: 0.27 to 4.71; log rank p=0.87). 
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 With a median clinical follow-up of 6.6 years, there were 19 disease progression events; 
10 on Arm C1 on Arm B, and 8 on Arm A. Radiographic progression was listed in the case 
report forms as the justification for determination of progression  in 18 patients, with the  
remaining patient listed as ‘local brain failure and clinical progression’. Median progression-free 
survival (FIGURE 3) was significantly shorter in TMZ alone-treated patients compared with 
those treated with RT (Arm A+B) (2.9 yrs. vs. not reached, respectively; HR=3.12, 95% CI: 1.26 
to 7.69; log rank p=0.009). The 3- and 5-year PFS rates were 50% and 33% in the TMZ alone-
treated patients, respectively, compared to 83% and 56% in those treated with RT (Arms A+B).  
There were six response-evaluable patients on each arm.  No statistical difference (p=0.52) was 
observed across arms for patients with a tumor response (REGR, partial response (PR), or 
complete response (CR) lasting at least 4-weeks:  there were no responses on Arm A (0%), 2 
responses on Arm B (33%), and 1 response on Arm C (17%). 
 
All of the Arm C patients who progressed on TMZ alone subsequently received RT or 
RT+TMZ, and 3 also underwent re-resection, all with pathologic confirmation of tumor 
progression. One progressing patient each on Arm A and Arm B underwent subsequent re-




Tissues from 35 of the 36 (97%) patients (Arm A - 12; Arm B - 11; Arm C - 12) were 
available for IDH analysis. Of these, 30 (86%) were IDH mutated (Arm A - 11; Arm B - 10; 
Arm C - 9) and 5 were IDH wild type (WT) (Arm A - 1; Arm B - 1; Arm C - 3).  IDH 1 and 2 
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WT status was confirmed by sequencing of available tumor tissue from 2/5 of these  patients; for 
the purposes of this analysis, the 3 remaining patients were considered IDH WT based on  IHC 
results alone, When comparing the IDH mutated and non-mutated patients, PFS differed, but did 
not reach statistical significance (median, 5.4 yrs. vs. 0.8 yrs., respectively; HR=0.35, 95% CI: 
0.12 to 1.06; log rank p = 0.052), but OS differed significantly (median = not reached vs. 2.0 
yrs., respectively; HR=0.07, 95% CI: 0.01 to 0.31; log rank p < 0.01). Cox regression was used 
to adjust for IDH mutation status. The model included IDH mutational status and RT treatment 
status as co-variables (Arm C vs pooled Arms A+B), as no significant interaction between these 
two variables was observed (OS, p=0.995; PFS, p=0.068). Again, PFS was shorter for patients 
who did not receive RT, (HR= 3.33; 95% CI: 1.31, 8.45; p=0.011). In the analysis of OS, RT 
treatment status (Arm C vs A+B) was not statistically associated with OS (HR = 2.78; 95% CI 




 No statistical difference was observed across treatment arms with respect to the 
proportion of patients with at least one Grade 3 or 4 adverse event (25%, 42%, and 33% on Arms 
A, B and C, respectively; p = 0.69). There was one patient in each arm that experienced a grade 4 
event and no grade 5 adverse events were observed. There were 2 patients on Arm A, 4 patients 
on Arm B, and 3 patients on Arm C that experienced grade 3 adverse events. Two RT-treated 
patients withdrew from treatment due to adverse events, one Arm A patient with empyema 
requiring surgery, and one Arm B with neutropenia. No Arm C patients withdrew from treatment 
due to adverse events.  





Twenty-nine (81%) patients completed the full cognitive test battery assessments for the 
baseline and 3-month time points (TABLE 2B). Overall, there was deterioration in at least one 
test results by > RCI90 at 3 months compared with baseline pre-treatment testing in 21 patients 
(72%). Of the patients demonstrating cognitive decline at 3 months, none met protocol-defined 
criteria for clinical progression. There was no significant difference in proportions of patients 
who declined (Arm C, 67%; Arms A and B, 75%  p=0.99).  Comparisons of individual subtests 
also did not yield statistically significant differences between Arm C versus Arms A and B.  
 
 
Quality of Life (QoL) 
 
QoL assessments for change from baseline to timepoint-1 (3 mos.) were available for 21 
patients in pooled Arms A and B, and 9 in Arm C.  Changes from baseline to timepoint-2 were 
available from 14 and 6 patients in arms A+B and Arm C, respectively.  There was no statistical 
difference between Arm A+B and Arm C as measured by the QLQ-C30 overall QoL.  Slight 
increases from baseline were noted in the averages for both groups of patients at both timepoint-
1 (Arms A+B: 5.6 points, Arm C: 4.6 points; p=0.89) and timepoint-2 (Arms A+ B: 7.1 points, 
Arm C: 4.2 points; p=0.67).  Two subscales showed statistically significant differences between 
Arms A+B versus Arm C for at least one time point: the QLQ-C30 subscale for constipation 
showed an average improvement at timepoint-1 for Arm C and no change in Arms A+ patients 
(18.5 points versus 0.0 points; p=0.002).  The QLQ-BN20 subscale for Motor Dysfunction 
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showed an average improvement at timepoint-2 for Arm C and a decline for patients in Arm 




 From 1985 to 2000, many physicians recommended treatment of 1p/19q codeleted 
patients with RT alone, or RT + PCV. In the 2000s, there was a shift to recommendation of 
either chemotherapy (PCV or TMZ), or RT + TMZ, 9 which occurred in the absence of 
comparative data from randomized prospective trials. As of this writing, TMZ has not yet been 
approved by the U.S. Food and Drug Administration for the specific indication of newly 
diagnosed WHO grade II or III oligodendroglioma. 
 
The original CODEL study was designed with an RT-alone control arm, as at the time 
there were no conclusive data demonstrating OS benefit with the addition of PCV chemotherapy 
to RT, compared with RT alone. At the time (2006), the initial analyses from the RTOG 9402 
and EORTC 26951 did not demonstrate superiority of RT+ PCV (neoadjuvant or adjuvant) over 
RT alone. 10,11 Accordingly, the main objective of the original CODEL study was to determine 
whether the addition of TMZ to RT might result in superior survival compared with RT alone, 
when (at the time) the addition of PCV to RT had not.  
 
The original CODEL design became obsolete after mature analyses from RTOG 9402 
and EORTC 26951 showed inferior survival with RT alone as compared with RT+PCV. 1, 2 Both 
randomized trials suggested that 1p/19q codeletion predicted benefit to addition of 
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chemotherapy, More recent reports suggest that O-6-methylguanine-DNA methyltransferase 
(MGMT) gene promoter hypermethylation and IDH mutation may be superior predictive factors. 
12, 13 The current WHO 2016 classification requires that both 1p/19q codeletion and IDH 
mutation be present for a diagnosis of oligodendroglioma. 14  
  
 The authors acknowledge the limitations of this study. The current analysis involved a 
small sample size and comparisons are likely underpowered. It is noted that central confirmation 
of radiographic progression was not performed, although the specific reasons for determination 
of progression was reviewed as documented in the protocol case report forms for each patient. 
We cannot completely exclude introduction of bias regarding timing of progression, however, 
this is felt unlikely. In review of the case report forms, radiographic progression was listed as the 
determining cause for all progressing patients except the latter progressing due to ‘local brain 
failure and clinical progression’. Furthermore, the definition of progression was clearly protocol-
specified, the NCI Cooperative Group, CCTG and EORTC site investigators are experienced in 
clinical trial conduct, and several different centers accrued patients to the different treatment 
arms.  
 
With these caveats in mind, our data showed that treatment with TMZ alone was 
associated with earlier time to tumor progression and significantly shorter PFS compared with 
those treated with radiotherapy (RT and RT + TMZ). Although the observed median PFS of 2.9 
years for newly-diagnosed codeleted patients treated with TMZ alone appears shorter than 
expected, it is similar to that previously reported in retrospective or prospective studies involving 
1p/19q codeleted patients treated with TMZ alone (TABLE 3), 15-19 Given our data and prior 
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reports indicating median PFS of 8.4-12.8 years with RT + PCV. 1,2, the Alliance Data 
Monitoring Committee and NCI recommended closure of the TMZ alone Arm in CODEL as it 
was felt that it would be unlikely that patients treated with TMZ alone would experience superior 
survival than those treated on the RT arms. Although OS was longer on the RT-containing arms 
it did not achieve statistical significance, but this comparison was underpowered. It is also 
possible that OS curves converged in part due to subsequent treatment, given that all patients 
treated with TMZ alone received RT-containing regimens at relapse. Based on these data and 
prior Phase III results, the ongoing CODEL trial has been re-designed as a two-arm comparison 
of RT followed by adjuvant PCV (control, based on RTOG 9402 and EORTC26951) versus RT 
with concomitant and adjuvant TMZ, with PFS as the primary endpoint. 
 
We did not find significant differences in cognitive function between treatment arms at 3 
months, but the number of patients tested was small and hence comparisons are underpowered. 
The lack of later assessment points precludes meaningful conclusions. Comprehensive 
mandatory serial cognitive and QoL assessments are required in the ongoing CODEL study, 
which we hope will clarify the comparative toxicities of RT+ PCV versus RT+TMZ. The 
comparative toxicities of PCV chemotherapy alone versus RT + PCV may also be clarified in the 
ongoing POLCA study (NCT02444000). 
 
In the original CODEL design, IDH status was not required for eligibility. We were able 
to retrospectively identify  IDH status retrospectively in 35/36 (97%) patients; 30 (86%) were 
IDH mutated (Arm A - 11; Arm B - 10; Arm C - 9) and 5 were IDH wild type (WT) (Arm A - 1; 
Arm B - 1; Arm C - 3). One might expect that IDH WT 1p/19q codeleted patients would show 
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earlier progression than IDH mutated patients, but when adjusting for IDH mutation status (WT 
vs. mut), treatment with RT (Arms A and B vs. C) remained significantly associated with longer 
PFS (HR= 3.33; 95% CI: 1.31, 8.45; p=0.011), and no significant interaction was observed 
between IDH mutation status and treatment with RT (p=0.068). One potential reason for this 
apparent discordance may be that only 2 of our 5 patients had confirmation of IDH WT status, as 
determined initially by IHC, with subsequent sequencing. It has been reported that almost all 
1p/19q codeleted oligodendroglial tumors show IDH 1 or 2 mutations by sequencing, and thus it 
is theoretically possible that IDH WT, as determined by IHC, represented false negatives in our 3 
patients. Nevertheless, we did observe significant differences in OS of codeleted patients as a 
function of IDH status.  Given the 2016 WHO definition of oligodendroglioma now requires 
both 1p/19q codeletion and IDH mutation for diagnosis,14  it is reasonable to consider the rare, 
1p/19q codeleted, IDH WT patients as a separate cohort for future trials. In accord with the 2016 
WHO definition, both 1p/19q codeletion and IDH mutation are now required as eligibility 
criteria in the ongoing CODEL study.  
 
It is acknowledged that certain patients with 1p/19q co-deleted, IDH mutated tumors 
even when treated with TMZ alone, can exhibit indolent disease. 12, 21-22  It has been postulated 
that such variation in biological behavior may in part be explained by additional genomic 
alterations within 1p/19q codeleted tumors.  The presence of 9p21, loss.14q loss, or MYC 
activation has been associated with unfavorable outcome in patients with 1p/19q codeleted 
tumors. 21 Conversely, overexpression of neuronal intermediate progenitor proteins has been 
associated with more indolent behavior. 22 It is expected that the comprehensive correlative 
multi-omics analyses which are part of the ongoing CODEL study might identify new 
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biomarkers that delineate prognostic subgroups, and identify important new potential therapeutic 




We found that treatment of newly diagnosed patients with 1p/19q codeleted WHO Grade 
III oligodendroglial tumors with TMZ alone was associated with significantly inferior PFS as 
compared with patients treated with RT. When combined with prior reported data, 1, 2   our 
results support the assertion that the current standard of care treatment for newly diagnosed 
patients with 1p/19q codeleted anaplastic gliomas should include both radiation and 
chemotherapy. The ongoing CODEL trial should establish the comparative efficacy and toxicity 
of RT plus adjuvant PCV versus RT plus concomitant and adjuvant TMZ, and the integrated 
correlative molecular analyses may identify prognostic subgroups and new therapeutic targets for 
this population.  
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FIGURE 2A.  OVERALL SURVIVAL (ARM A vs. ARM B) 
 
FIGURE 2B.  OVERALL SURVIVAL (ARMS A+B vs. ARM C) 
 





NCCTG ASSESSMENT CRITERIA FOR RESPONSE AND PROGRESSION 
 
Assessment of response was based upon a) changes on enhanced MRI (or CT) scans, 
obtained at the protocol-defined timepoints and compared with baseline on-study scans, and b) 
clinical status, based on neurologic examination, performed at protocol-defined timepoints and 
compared with baseline examination. Patients whose postoperative scans revealed no residual 
tumor were classified as NED (no evidence of disease). To be evaluable for objective response 
(CR, PR or STAB), patients must have had response of measurable or evaluable disease on MRI 
(or CT) scan while remaining neurologically stable or improved, on stable or decreased doses of 
corticosteroids.  
 
For the purposes of this study, response or progression status at the timing of assessment 
was as compared with status at baseline. Time to progression was defined as the time from 
randomization to time of progression. 
 
COMPLETE RESPONSE (CR): disappearance of all visible tumor.  
 
PARTIAL RESPONSE (PR): >50% reduction in the product of perpendicular diameters of the 
clearly demarcated contrast-enhancing mass.  
 
REGRESSION (REGR): (Only for tumors not bi-dimensionally measurable, but clearly 
evaluable for response):  unequivocal reduction in the size of contrast enhancement, or decrease 
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in mass effect, as agreed upon independently by the primary physician and the quality control 
physician.  
 
STABLE DISEASE (STAB): <50% reduction to < 25% increase in the product of 
perpendicular diameters of the clearly demarcated contrast-enhancing mass 
 
PROGRESSION: 25% or greater increase in the product of perpendicular diameters of the 
clearly demarcated contrast enhancing mass, unequivocal progression of non-measurable 


















Group, n (%)    
EORTC 6 (50.0%) 5 (41.7%) 6 (50.0%) 
North America 6 (50.0%) 7 (58.3%) 6 (50.0%) 
    
Age (years)    
N 12 12 12 
Mean (SD) 48.3 (10.28) 48.3 (9.19) 42.5 (12.97) 
Median 50.0 48.5 43.5 
Range 29.0, 66.0 31.0, 64.0 18.0, 61.0 
    
Gender, n (%)    
Female 3 (25.0%) 6 (50.0%) 2 (16.7%) 
Male 9 (75.0%) 6 (50.0%) 10 (83.3%) 
    
ECOG Performance 
Score, n (%) 
   
0 9 (75.0%) 8 (66.7%) 9 (75.0%) 
1 3 (25.0%) 4 (33.3%) 3 (25.0%) 
    
Previous Cancer, n (%)    
Yes 1 (8.3%) 0 (0.0%) 0 (0.0%) 
No 11 (91.7%) 12 (100.0%) 12 (100.0%) 
    
Side Primary 
Tumor, n (%) 
   
Right 6 (50.0%) 8 (66.7%) 9 (75.0%) 
Left 5 (41.7%) 3 (25.0%) 3 (25.0%) 
Bilateral 1 (8.3%) 1 (8.3%) 0 (0.0%) 
    
Corticosteroid 
Therapy at Entry, n (%) 
   
Yes 3 (25.0%) 1 (8.3%) 4 (33.3%) 
No 9 (75.0%) 11 (91.7%) 8 (66.7%) 
    
Extent Surgical 
Resection, n (%) 
   
Biopsy 0 (0.0%) 1 (8.3%) 2 (16.7%) 
Subtotal Resection 6 (50.0%) 6 (50.0%) 4 (33.3%) 
Gross Total Resection 6 (50.0%) 5 (41.7%) 6 (50.0%) 
    
Prior History 
Brain Tumor, n (%) 
   
Yes 1 (8.3%) 0 (0.0%) 1 (8.3%) 
No 11 (91.7%) 12 (100.0%) 11 (91.7%) 
 
TABLE 2.  
COGNITIVE PROGRESSION AT 3 MONTHS 
























Frequency of Deteriorationa 
HVLT-R Immediate 






















































































a > RCI90 value decrease from baseline 
b Number deteriorating on any one subtest > RCI90 value decrease from baseline 
c Defined by clinical exam and/ or radiographic progression at 3 months after registration 
1 Chi-Square  
2 Kruskal-Wallis  
RCI=Reliable Change Index; HVLT-R=Hopkins Verbal Learning Test-Revised; COWAT=Controlled Oral Word 
Association Test; RT=radiotherapy; TMZ=temozolomide 
TABLE 3. 
PROGRESSION OUTCOME FOLLOWING INITIAL CHEMOTHERAPY ALONE: 




Authors Study Type N 
Initial 
Treatment 
Med PFS or 
Med TTP, (yrs) 





Mikkelsen, et al16 Case Series 36 TMZ 2.4 
Thomas, et al18 Phase II 33 TMZ → ASCTb 5 








a 1p/19q codeleted, CIMP + patients  
b Responders to TMZ subsequently received ASCT  
AO=anaplastic oligodendroglioma; AOA=anaplastic oligoastrocytoma; Med=Median; 
TMZ=temozolomide; PCV=procarbazine, lomustine and vincristine; HDC-ASCT=high dose 
chemotherapy with autologous stem cell transplant 
 
 




